EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1

Laura de-la-Puente-Ovejero iD, Ana Fernández-Rodríguez iD, Sarah Francoz, Gonzalo Aizpurua, Lucía Lomba-Riego, Matthias Drosten, Carmen Guerra, Mónica Musteanu iD, Mariano Barbacid, Sara García-Alonso iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0341778 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Laura de-la-Puente-Ovejero und 9 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-raf, Proto-Oncogene Proteins p21(ras), Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, Comunidad de Madrid, Agencia Estatal de Investigación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/objectives KRAS-mutant lung adenocarcinoma remains without effective targeted therapies for most patients, particularly those with non-G12C alleles or resistance to KRAS G12C inhibitors. RAF1 is essential for KRAS-driven tumor maintenance through kinase-independent survival functions, making it an attractive candidate for targeted protein degradation. However, the therapeutic impact and safety of co-targeting RAF1 with related kinases remain unclear.

Methods

We used dual-recombinase genetically engineered mouse models of Kras +/G12V ;Trp53 -/- lung cancer to evaluate the effects of Raf1 ablation alone or in combination with Araf , Egfr , or Ddr1 . Lung tumors were initiated by intranasal Ad5-CMV-FLPo delivery and allowed to reach CT-detectable size before inducing systemic gene deletion via tamoxifen-activated CreERT2. Tumor burden was monitored by longitudinal CT imaging and classified using RECIST-like criteria. Toxicity was assessed by body weight monitoring, histopathology of major organs, and survival analysis.

Results

Raf1 deletion induced robust tumor regression within two months, in more than 60% of lesions. Araf ablation alone or combined with Raf1 did not affect tumor initiation, progression, or regression rates. Similarly, neither genetic nor pharmacological EGFR inhibition (afatinib) improved responses to Raf1 ablation. Ddr1 co-deletion also failed to enhance therapeutic efficacy and slightly reduced response rates. None of the dual-targeting strategies increased systemic toxicity.

Conclusions

RAF1 is a key, non-redundant vulnerability in KRAS-driven lung adenocarcinoma. Co-targeting ARAF, EGFR, or DDR1 provides no additional therapeutic benefit in established disease. The absence of adverse effects from ARAF co-deletion suggests that RAF1 degraders with partial cross-activity towards ARAF are likely to be safe. These findings provide a strong preclinical rationale for developing RAF1-targeted degradation as a monotherapy for these malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-rafProto-Oncogene Proteins p21(ras)Lung NeoplasmsAdenocarcinoma of LungAnimalsErbB ReceptorsMiceHumansFemale

Substanzen

Proto-Oncogene Proteins c-rafErbB ReceptorsProto-Oncogene Proteins p21(ras)Raf1 protein, mouseHras protein, mouse

Autor:innen und Institutionen

  • Experimental Oncology Group, Tumor Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
  • RAS Signalling and Lung Cancer Group, Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, Consejo Superior de Investigaciones Científicas-Universidad de Salamanca, Salamanca, Spain.
  • Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Universidad Complutense de Madrid, Madrid, Spain.
  • Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

ORCID-Profile: Laura de-la-Puente-Ovejero, Ana Fernández-Rodríguez, Mónica Musteanu, Sara García-Alonso

Förderung

  • Ministerio de Ciencia e Innovación
  • Comunidad de Madrid
  • Agencia Estatal de Investigación
  • Centro de Investigación Biomédica en Red de Cáncer
  • 'la Caixa' Foundation

Zitieren

APA

de-la-Puente-Ovejero, L., Fernández-Rodríguez, A., Francoz, S., Aizpurua, G., Lomba-Riego, L., Drosten, M., Guerra, C., Musteanu, M., Barbacid, M., & García-Alonso, S. (2026). RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1. PLOS One. https://doi.org/10.1371/journal.pone.0341778

Vancouver

de-la-Puente-Ovejero L, Fernández-Rodríguez A, Francoz S, Aizpurua G, Lomba-Riego L, Drosten M, et al. RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1. PLOS One. 2026. doi:10.1371/journal.pone.0341778

BibTeX
@article{delaPuenteOvejero2026,
  author = {de-la-Puente-Ovejero, Laura and Fernández-Rodríguez, Ana and Francoz, Sarah and Aizpurua, Gonzalo and Lomba-Riego, Lucía and Drosten, Matthias and Guerra, Carmen and Musteanu, Mónica and Barbacid, Mariano and García-Alonso, Sara},
  title = {RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0341778}
}
Kostenlos starten →